REPORT HIGHLIGHT
C-reactive Protein Testing Market size was valued at USD 5,633 Million in 2023, expanding at a CAGR of 1.5% from 2024 to 2032.
An acute-phase protein called C-reactive protein (CRP) is created by the liver and is released into the bloodstream in response to inflammatory conditions. The level of CRP in blood plasma is measured using the c-reactive protein (CRP) test.
C-reactive Protein Testing Market- Market Dynamics
Increasing prevalence of CVD to propel market demand
According to the World Health Organization, cardiovascular disease is one of the main causes of mortality globally. C-reactive protein is a very useful tool for predicting a person's chance of having a heart attack or stroke. C-reactive protein measures the risk of atherosclerosis, making it a reliable marker for CVD detection. Plaque accumulation inside the arteries causes inflammation inside the artery walls, a condition known as atherosclerosis. This has increased the need for prompt and effective diagnosis techniques, which has sped up the use of CRP testing to identify cardiovascular disease. Furthermore, during the forecast period, it is anticipated that continued research into the function of C-reactive protein in cardiovascular illnesses would accelerate market revenue growth.
C-reactive Protein Testing Market- Key Insights
- As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 1.5% over the forecast period (2024-2032)
- Based on assay type segmentation, the Immunoturbidimetric assays segment is expected to dominate the market during the forecast period
- Based on application segmentation, the cardiovascular disease segment is expected to hold the largest market share over the forecast period
- Based on region, North America is expected to dominate the market over the forecast period
C-reactive Protein Testing Market- Segmentation Analysis:
- The Global C-reactive Protein Testing Market is segmented based on Assay Type, Application, and Region.
- Based on the assay type, the C-reactive Protein Testing market is divided into Chemiluminescence Immunoassay (CLIA), Enzyme-linked immunosorbent assay (ELISA), Immunoturbidimetric assays and Others. The Immunoturbidimetric assays segment is expected to dominate the market during the forecast period. The development and availability of affordable automated immunoturbidimetric assays with excellent sensitivity for assessing a broad range of CRP levels is anticipated to drive the segment's revenue growth. Clinical biochemistry routinely analyses CRP and high-sensitivity CRP using these tests, which are markers of systemic inflammation and atherosclerosis risk. Furthermore, it is projected that the growing research efforts concerning immunoturbidimetric assays will further bolster this segment's revenue development over the long run.
- Based on the application, the C-reactive Protein Testing industry is categorized into Cardiovascular Disease, Inflammatory Bowel Disease, Diabetes, Rheumatoid Arthritis and Others. The Cardiovascular Disease segment is expected to hold the largest market share over the forecast period. An increase in the prevalence of CVDs is the key factor leading to the growth of the CRP testing market acts as a vital marker and indication for diagnosing CVDs by measuring the risk of atherosclerosis. Patients with cardiovascular diseases (CVDs) frequently have elevated CRP levels, and tests can identify even very low CRP levels. As a consequence, throughout the projection period, the revenue growth of this sector will be driven by the notable increase in the usage of CRP testing for the identification of cardiovascular illnesses.
C-reactive Protein Testing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period. This segment's dominance is probably due to a number of factors, including increased cardiovascular disease incidence, increasing product releases, the existence of established businesses, technical improvements, and a well-developed healthcare infrastructure. Furthermore, a study by Roosevelt University College of Pharmacy in the United States published in Frontiers in Immunology in September 2020 titled "How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression" states that because the functional bioactivity of the CRP test-which has been a largely undefined prototypical acute phase reactant for decades-diagnostics of a wide range of conditions and diseases use CRP blood levels as a straightforward indicator of ongoing inflammation. These investigations will encourage more people to use CRP testing to diagnose inflammation in the body.
C-reactive Protein Testing Market- Competitive Landscape:
The key players operating in the market are: Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Abbott Laboratories, Zoetis Inc. (Abaxis Inc.), Randox Laboratories Limited, F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter Inc.), Merck KGAA (Millipore Sigma), Horiba, Ltd. and Laboratory Corporation of America Holdings among others.
Recent Developments:
In January 2022, LumiraDx's C-reactive protein PCR test received CE mark certification. This microfluidic immunoassay test is small, lightweight, completely automated, and can detect C-reactive protein quantitatively in as little as four minutes.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL C-REACTIVE PROTEIN TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific, Inc.
- Zoetis Inc. (Abaxis Inc.)
- Randox Laboratories Limited
- Danaher Corporation (Beckman Coulter Inc.)
- Merck KGAA (Millipore Sigma)
- Laboratory Corporation of America Holdings
GLOBAL C-REACTIVE PROTEIN TESTING MARKET, BY ASSAY TYPE- MARKET ANALYSIS, 2019 - 2032
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-linked immunosorbent assay (ELISA)
- Immunoturbidimetric assays
- Others
GLOBAL C-REACTIVE PROTEIN TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Cardiovascular Disease
- Inflammatory Bowel Disease
- Diabetes
- Rheumatoid Arthritis
- Others
GLOBAL C-REACTIVE PROTEIN TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA